



Press release, November 15, 2018

## **Bulletin from Annual General Meeting of Diamyd Medical AB**

The Annual General Meeting of Diamyd Medical AB (publ) was held on November 15, 2018.

The Company's income statement and balance sheet were adopted, and the Board members and the Chief Executive Officer were discharged from liability for the fiscal year 2017/2018. The Annual General Meeting approved the Board's proposal that no dividend be paid for the fiscal year 2017/2018.

Erik Nerpin was re-elected as Chairman of the Board and Anders Essen-Möller, Maria-Teresa Essen-Möller and Torbjörn Bäckström were re-elected to the Board. Mark A. Atkinson was elected as new Board member. Professor Atkinson, American Diabetes Association Eminent Scholar for Diabetes Research, is Director of the UF Diabetes Institute at University of Florida, USA, and a world-leading diabetes expert.

The Annual General Meeting approved the proposed remuneration to Board members and the Chairman of the Board.

The Annual General Meeting resolved to re-elect the auditing company BDO until the end of the Annual General Meeting 2019. Principal auditor is the authorized public accountant Johan Pharmanson.

The Annual General Meeting resolved to authorize the Board, on one or more occasions prior to the next Annual General Meeting to issue shares and to deviate from the shareholders' preferential rights when so doing. Payment may be made in cash, through a contribution or by offsetting. In a share issue for cash payment and in deviation from the shareholders' preferential rights, the number of shares issued pursuant to the authorization may not exceed 20 percent of the shares in the Company when the share issue occurs.

### **About Diamyd Medical**

Diamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd<sup>®</sup>, for antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Diamyd<sup>®</sup> has demonstrated good safety in trials with more than 1,000 patients as well as effect in some pre-specified subgroups. Besides the Company's own European Phase-II trial DIAGNODE-2, where the diabetes vaccine is administered directly into the lymph node, there are four investigator initiated clinical trials ongoing with Diamyd<sup>®</sup>. Diamyd Medical also develops Remygen<sup>®</sup>, an oral GABA-based investigational drug. An investigator-initiated trial in patients with type 1 diabetes since at least five years has started at Uppsala University Hospital. An investigator-initiated placebo-controlled trial with GABA and Diamyd<sup>®</sup> in patients recently diagnosed with type 1 diabetes is ongoing at the University of Alabama at Birmingham. Exclusive licenses for GABA and positive allosteric modulators of GABA receptors for the treatment of diabetes and inflammatory diseases constitutes alongside with the diabetes vaccine Diamyd<sup>®</sup> and Remygen<sup>®</sup> key assets. Diamyd Medical is also one of the major shareholders in the stem cell company NextCell Pharma AB and has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA.

Diamyd Medical's B-share is traded on Nasdaq First North under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.

### **For further information, please contact:**

Ulf Hannelius, President and CEO

Phone: +46 736 35 42 41

E-mail: [ulf.hannelius@diamyd.com](mailto:ulf.hannelius@diamyd.com)

**Diamyd Medical AB (publ)**

Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68

E-mail: [info@diamyd.com](mailto:info@diamyd.com) Reg. no.: 556242-3797 Website: <https://www.diamyd.com>